Skip to main content
SpringerLink
Log in

Knochenmetastasen bei urologischen Malignomen

  • Chapter
  • First Online:
Knochenmetastasen

  • 1883 Accesses

Zusammenfassung

Ein großer Anteil der Patienten mit urologischen Malignomen in fortgeschrittenen Stadien entwickelt im Verlauf der Erkrankung Knochenmetastasen. Beim Prostatakarzinom wird die Knochenstabilität zusätzlich durch die therapiebedingte Androgenablation beeinträchtigt. Eine antiresorptive Therapie durch Bisphosphonate oder RANK-Ligand Inhibitoren kann das Risiko für skelettassoziierte Komplikationen signifikant reduzieren. Bei Patienten mit ossär metastasiertem Prostatakarzinom steht zusätzlich das Radionuklid Alpharadin als Behandlungsmethode zur Verfügung. Während für die Behandlung des ossär metastasierten Prostatakarzinoms die Ergebnisse zahlreicher randomisierter Phase-III-Studien vorliegen, ist die Datenlage zum Einsatz von antiresorptiven Substanzen beim metastasierten Urothel- und Nierenzellkarzinom begrenzt, und aktuelle Empfehlungen basieren auf Studien mit kleinen Fallzahlen oder Subgruppenanalysen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 79.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • Araujo JC, Mathew P, Armstrong AJ et al (2012) Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1–2 study. Cancer 118(1): 63–71

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Batson OV (1967) The vertebral system of veins as a means for cancer dissemination. Prog Clin Cancer 3: 1–18

    CAS  PubMed  Google Scholar 

  • Beer T et al. (2014) Enzalutamide decreases risk of death and delays progression in phase 3 trial of men with metastatic prostate cancer. Presentation, ASCO Genitourinary Cancers Symposium 2014

    Google Scholar 

  • Berruti A, Dogliotti L, Bitossi R et al (2000) Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. J Urol 164(4): 1248–1253

    Article  CAS  PubMed  Google Scholar 

  • Berruti A, Tucci M, Mosca A et al (2005) Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease. Br J Cancer 93(6): 633–638

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Brunello A, Saia G, Bedogni A et al (2009) Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma. Bone 44(1): 173–175

    Article  CAS  PubMed  Google Scholar 

  • Bubendorf L, Schopfer A, Wagner U et al (2000) Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 31(5): 578–583

    Article  CAS  PubMed  Google Scholar 

  • Dearnaley DP, Mason MD, Parmar MK et al (2009) Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol 10(9): 872–876

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Demers LM, Costa L, Lipton A (2000) Biochemical markers and skeletal metastases. Cancer 88(12 Suppl): 2919–2926

    Google Scholar 

  • Dennis ER, Jia X, Mezheritskiy IS et al (2012) Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer. J Clin Oncol 30(5): 519–524

    Article  PubMed Central  PubMed  Google Scholar 

  • Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2): 228–247

    Article  CAS  PubMed  Google Scholar 

  • Ernst DS, Tannock IF, Winquist EW et al (2003) Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol 21(17): 3335–3342

    Article  CAS  PubMed  Google Scholar 

  • Fizazi K, Carducci M, Smith M et al (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377(9768): 813–822

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Fizazi K, Scher HI, Molina A et al (2012) Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13(10): 983–992

    Article  CAS  PubMed  Google Scholar 

  • Giannarini G, Kessler TM, Thoeny HC et al (2010) Do patients benefit from routine follow-up to detect recurrences after radical cystectomy and ileal orthotopic bladder substitution? Eur Urol 58(4): 486–494

    Article  PubMed  Google Scholar 

  • Green JR, Muller K, Jaeggi KA (1994) Preclinical pharmacology of CGP 42’446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 9(5): 745–751

    Article  CAS  PubMed  Google Scholar 

  • Groot MT, Boeken Kruger CG, Pelger RC, Uyl-de Groot CA (2003) Costs of prostate cancer, metastatic to the bone, in The Netherlands. Eur Urol 43(3): 226–232

    Article  CAS  PubMed  Google Scholar 

  • Henry DH, Costa L, Goldwasser F et al (2011) Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29(9): 1125–1132

    Article  CAS  PubMed  Google Scholar 

  • Hussain SA, Weston R, Stephenson RN et al (2003) Immediate dual energy X-ray absorptiometry reveals a high incidence of osteoporosis in patients with advanced prostate cancer before hormonal manipulation. BJU Int 92(7): 690–694

    Article  CAS  PubMed  Google Scholar 

  • Imbriaco M, Larson SM, Yeung HW et al (1998) A new parameter for measuring metastatic bone involvement by prostate cancer: the Bone Scan Index. Clin Cancer Res 4(7): 1765–1772

    CAS  PubMed  Google Scholar 

  • Izumi K, Mizokami A, Itai S et al (2012) Increases in bone turnover marker levels at an early phase after starting zoledronic acid predicts skeletal-related events in patients with prostate cancer with bone metastasis. BJU Int 109(3): 394–400

    Article  CAS  PubMed  Google Scholar 

  • Jiang HX, Majumdar SR, Dick DA et al (2005) Development and initial validation of a risk score for predicting in-hospital and 1-year mortality in patients with hip fractures. J Bone Miner Res 20(3): 494–500

    Article  CAS  PubMed  Google Scholar 

  • Lee N, Fawaaz R, Olsson CA et al (2000) Which patients with newly diagnosed prostate cancer need a radionuclide bone scan? An analysis based on 631 patients. Int J Radiat Oncol Biol Phys 48(5): 1443–1446

    Article  CAS  PubMed  Google Scholar 

  • Lipton A, Zheng M, Seaman J (2003) Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer 98(5): 962–969

    Article  CAS  PubMed  Google Scholar 

  • Lipton A, Colombo-Berra A, Bukowski RM et al (2004) Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid. Clin Cancer Res 10(18 Pt 2): 6397S–6403S

    Article  CAS  PubMed  Google Scholar 

  • Logothetis CJ, Lin SH (2005) Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer 5(1): 21–28

    Article  CAS  PubMed  Google Scholar 

  • Logothetis CJ, Basch E, Molina A et al (2012) Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol 13(12): 1210–1217

    Article  CAS  PubMed  Google Scholar 

  • Lorente JA, Morote J, Raventos C et al (1996) Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer. J Urol 155(4): 1348–1351

    Article  CAS  PubMed  Google Scholar 

  • Mason MD, Sydes MR, Glaholm J et al (2007) Oral sodium clodronate for nonmetastatic prostate cancer – results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873). J Natl Cancer Inst 99(10): 765–776

    Article  CAS  PubMed  Google Scholar 

  • Meulenbeld HJ, van Werkhoven ED, Coenen JL et al (2012) Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro). Eur J Cancer 48(16): 2993–3000

    Article  CAS  PubMed  Google Scholar 

  • Motzer RJ, Mazumdar M, Bacik J et al (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17(8): 2530–2540

    CAS  PubMed  Google Scholar 

  • Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(2): 115–124

    Article  CAS  PubMed  Google Scholar 

  • Motzer RJ, Escudier B, Oudard S et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372(9637): 449–456

    Article  CAS  PubMed  Google Scholar 

  • Mulders PF, Miller K, Tchekmedyian NS (2007) Zoledronic acid reduces long-term risk of skeletal complications in patients with advanced renal cell carcinoma or bladder cancer. J Urol 177(4): 429–430

    Google Scholar 

  • Parker C, Heinrich D, Helle SI et al (2012) Overall survival benefit and impact on skeletal-related events for radium-223 chloride (Alpharadin) in the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases: a phase III randomized trial (ALSYMPCA). Eur Urol Suppl 11(1): E130–U523

    Article  Google Scholar 

  • Patil S, Figlin RA, Hutson TE et al (2011) Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol 22(2): 295–300

    Article  CAS  PubMed  Google Scholar 

  • Patrick D, Cleeland C, Fallowfield L et al (2012) Pain interference with daily functioning in patients with castrate-resistant prostate cancer: a comparison of denosumab and zoledronic acid. J Urol 187(4): E384–E384

    Article  Google Scholar 

  • Popiolek M, Rider JR, Andren O et al (2013) Natural history of early, localized prostate cancer: a final report from three decades of follow-up. Eur Urol 63(3): 428–435

    Article  PubMed  Google Scholar 

  • Pound CR, Partin AW, Eisenberger MA et al (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281(17): 1591–1597

    Article  CAS  PubMed  Google Scholar 

  • Rana A, Karamanis K, Lucas MG, Chisholm GD (1992) Identification of metastatic disease by T category, Gleason score and serum PSA level in patients with carcinoma of the prostate. Br J Urol 69(3): 277–281

    Article  CAS  PubMed  Google Scholar 

  • Roodman GD (2004) Mechanisms of bone metastasis. Discov Med 4(22): 144–148

    PubMed  Google Scholar 

  • Ryan CJ, Smith MR, de Bono JS et al (2013) Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368(2): 138–148

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Saad F, Gleason DM, Murray R et al (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94(19): 1458–1468

    Article  CAS  PubMed  Google Scholar 

  • Saad F, Gleason DM, Murray R et al (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96(11): 879–882

    Article  CAS  PubMed  Google Scholar 

  • Sartor O, Reid RH, Hoskin PJ et al; Quadramet 424Sm10/11 Study Group (2004) Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 63(5): 940–945

    Article  PubMed  Google Scholar 

  • Sartor O, Heinrich D, Helle SI et al (2012) Radium-223 chloride (Alpharadin) impact on overall survival and skeletal-related events in patients with castration-resistant prostate cancer with bone metastases: a phase III randomized trial (Alsympca). J Urol 187(4): E279–E279

    Article  Google Scholar 

  • Scher HI, Halabi S, Tannock I et al (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26(7): 1148–1159

    Article  PubMed Central  PubMed  Google Scholar 

  • Scher HI, Fizazi K, Saad F et al (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367(13): 1187–1197

    Article  CAS  PubMed  Google Scholar 

  • Sengelov L, Kamby C, von der Maase H (1996) Pattern of metastases in relation to characteristics of primary tumor and treatment in patients with disseminated urothelial carcinoma. J Urol 155(1): 111–114

    Article  CAS  PubMed  Google Scholar 

  • Shiozawa Y, Pedersen EA, Havens AM et al (2011) Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest 121(4): 1298–1312

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Small EJ, Smith MR, Seaman JJ et al (2003) Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 21(23): 4277–4284

    Article  CAS  PubMed  Google Scholar 

  • Smith MR, Saad F, Coleman R et al (2012a) Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 379(9810): 39–46

    Article  CAS  Google Scholar 

  • Smith M, Saad F, Shore ND et al (2012b) Effect of denosumab on prolonging bone-metastasis-free survival (BMFS) in men with nonmetastatic castrate-resistant prostate cancer (CRPC) presenting with aggressive PSA kinetics. J Clin Oncol 30(Suppl 5): 6

    Google Scholar 

  • Smith MR, Halabi S, Ryan CJ et al (2014) Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: Results of CALGB 9002 (Alliance). J Clin Oncol 32(11): 1143–1150

    Article  CAS  PubMed  Google Scholar 

  • Smith DC, Smith MR, Sweeney C et al (2013) Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol 31(4): 412–419

    Article  CAS  PubMed  Google Scholar 

  • Sonpavde G, Pond GR, Berry WR et al (2012) Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. Urol Oncol 30(5): 607–613

    Article  CAS  PubMed  Google Scholar 

  • Stein JP, Lieskovsky G, Cote R et al (2001) Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19(3): 666–675

    CAS  PubMed  Google Scholar 

  • Stenzl A, Cowan NC, De Santis M et al; European Association of European Association of Urology (2011) Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Actas Urol Esp 36(8): 449–60

    Google Scholar 

  • Todenhofer T, Hennenlotter J, Schmiedel BJ et al (2013) Alterations of the RANKL pathway in blood and bone marrow samples of prostate cancer patients without bone metastases. Prostate 73(2): 162–168

    Article  PubMed  Google Scholar 

  • Ulmert D, Kaboteh R, Fox JJ et al (2012) A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index. Eur Urol 62(1): 78–84

    Article  PubMed Central  PubMed  Google Scholar 

  • Vogel CL, Yanagihara RH, Wood AJ et al (2004) Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy. Oncologist 9(6): 687–695

    Article  CAS  PubMed  Google Scholar 

  • Volkmer BG, Kuefer R, Bartsch GC et al (2009) Oncological follow-up after radical cystectomy for bladder cancer – is there any benefit? J Urol 181(4): 1587–1593; discussion 1593

    Google Scholar 

  • Wang CY, Wu GY, Shen MJ et al (2013) Comparison of distribution characteristics of metastatic bone lesions between breast and prostate carcinomas. Oncol Lett 5(1): 391–397

    PubMed Central  PubMed  Google Scholar 

  • Weckermann D, Muller P, Wawroschek F et al (2001) Disseminated cytokeratin positive tumor cells in the bone marrow of patients with prostate cancer: detection and prognostic value. J Urol 166(2): 699–703

    Article  CAS  PubMed  Google Scholar 

  • Weinfurt KP, Li Y, Castel LD et al (2005) The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 16(4): 579–584

    Article  CAS  PubMed  Google Scholar 

  • Wirth M, Tammela T, Cicalese V et al (2014) Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS). Eur Urol. 2014 Feb 20. pii: S0302-2838(14)00133-X, epub ahead of print]

    Google Scholar 

  • Wood SL, Brown JE (2012) Skeletal metastasis in renal cell carcinoma: current and future management options. Cancer Treat Rev 38(4): 284–291

    Article  PubMed  Google Scholar 

  • Woodward E, Jagdev S, McParland L et al (2011) Skeletal complications and survival in renal cancer patients with bone metastases. Bone 48(1):160–166

    Article  PubMed  Google Scholar 

  • Yafi FA, Aprikian AG, Chin JL et al (2011) Contemporary outcomes of 2287 patients with bladder cancer who were treated with radical cystectomy: a Canadian multicentre experience. BJU Int 108(4): 539–545

    Article  PubMed  Google Scholar 

  • Yafi FA, Aprikian AG, Fradet Y et al (2012) Surveillance guidelines based on recurrence patterns after radical cystectomy for bladder cancer: the Canadian Bladder Cancer Network experience. BJU Int 110(9): 1317–1323

    Article  PubMed  Google Scholar 

  • Yasuda Y, Fujii Y, Yuasa T et al (2012) Possible improvement of survival with use of zoledronic acid in patients with bone metastases from renal cell carcinoma. Int J Clin Oncol 18(5): 877–883

    Article  PubMed  Google Scholar 

  • Yuen KK, Shelley M, Sze WM et al (2006) Bisphosphonates for advanced prostate cancer. Cochrane Database Syst Rev (4): CD006250

    Google Scholar 

  • Zekri J, Ahmed N, Coleman RE, Hancock BW (2001) The skeletal metastatic complications of renal cell carcinoma. Int J Oncol 19(2): 379–382

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Universitätsklinikum Tübingen, Klinik für Urologie, Hoppe-Seyler-Str. 3, 72076, Tübingen, Deutschland

    Tilman Todenhöfer

  2. Universitätsklinikum Tübingen, Universitätsklinik für Urologie, Hoppe-Seyler-Str. 3, 72076, Tübingen, Deutschland

    Arnulf Stenzl

Authors
  1. Tilman Todenhöfer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Arnulf Stenzl
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tilman Todenhöfer .

Editor information

Editors and Affiliations

  1. Universitätsklinik für Urologie, Universitätsklinikum Tübingen, Tübingen, Germany

    Arnulf Stenzl

  2. Universitätsfrauenklinik Düsseldorf, Düsseldorf, Germany

    Tanja Fehm

  3. Medizinische Klinik III, Bereich Endokrinologie, Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Germany

    Lorenz C. Hofbauer

  4. Orthopädisches Zentrum für Muskuloskelettale Forschung, Universität Würzburg, Würzburg, Germany

    Franz Jakob

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Todenhöfer, T., Stenzl, A. (2014). Knochenmetastasen bei urologischen Malignomen. In: Stenzl, A., Fehm, T., Hofbauer, L., Jakob, F. (eds) Knochenmetastasen. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-43471-0_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-43471-0_14

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-43470-3

  • Online ISBN: 978-3-662-43471-0

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation